Rotigotine protects dopaminergic neurons by targeting serotonin 1A receptors on astrocytes
Objective: In this study, we examined neuroprotective effects of rotigotine and involvement of serotonin 1A (5-HT1A) receptors on astrocytes in neuroprotective action of the drug…Effects of Rock Steady Boxing on Activities of Daily Living and Motor Symptoms of Parkinson’s Disease
Objective: To determine the impact of the Rock Steady Boxing (RSB) program on Parkinson’s disease (PD). To assess the feasibility of data collection for activities…VY-AADC01 gene therapy in Parkinson’s disease: Interim results of the on-going Phase 1b PD-1101 trial
Objective: Evaluate the safety of VY-AADC01, an AAV2 gene therapy vector with human aromatic L-amino acid decarboxylase (AADC) administered bilaterally to the putamen using intraoperative…Perceived Psychosocial Impacts of a Therapeutic Yoga Intervention for Individuals with Parkinson’s Disease (PD)
Objective: This qualitative study sought to understand the psychosocial impacts of a therapeutic yoga intervention for individuals with PD originally designed to improve balance and…Effects of JN403, an α-7-nicotine-acetylcholine-receptor (α7-nAChR) agonist on human alpha-synuclein-mediated in vitro and in vivo models of Parkinson’s disease
Objective: To investigate whether JN403, a novel selective agonist of α-7-nicotine-acetylcholine-receptors (α7-nAChRs) can suppress inflammation and toxicity in human alpha-synuclein (αSyn) induced in vitro and…A Double-Blind, Randomized, Placebo-Controlled, Cross-Over Phase IIa Trial to Evaluate the Efficacy of CVXL-0107 on Parkinson-Related Symptoms and Levodopa-Induced Dyskinesia in Advanced Parkinson’s Disease
Objective: To evaluate the efficacy of CVXL-0107 on motor symptoms and on levodopa-induced dyskinesia in advanced Parkinson’s disease (PD) patients. Background: CVXL-0107 is a glutamate…The Akt/mTOR/P70S6K/4EB-P1 signaling pathway is activated by metformin in a toxin-induced cellular model of Parkinson’s disease
Objective: To investigate the effects of metformin on the Akt/mTOR/P70S6K/4EB-P1 signaling pathway in a cellular model of Parkinson’s disease (PD). Background: Metformin is a drug…An investigation of the potential neuroprotective role of curcumin in Parkinson’s disease patient-derived fibroblasts
Objective: To investigate if the protective effects of curcumin previously observed in SH-SY5Y cells are also found in patient-derived fibroblasts from Parkinson’s disease patients. Background:…Prevalence of Single Nucleotide Polymorphisms (SNPs) rs362307 or rs362331 in Patients with Huntington’s Disease
Objective: An observational research study is being conducted in patients with Huntington’s disease (HD) to determine the frequency with which the thymine (T) variant of…Therapeutic exposures of CX-8998, a potent, selective and state dependent Cav3 channel antagonist in development for Essential Tremor and Parkinson’s disease Tremor in Cav3 driven neurological models
Objective: In this study, we utilized preclinical data to establish predicted human therapeutic exposures of the potent, selective and state-dependent Cav3 channel antagonist, CX-8998, currently…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- 13
- Next Page »